Medicarpin suppresses lung cancer cell growth in vitro and in vivo by inducing cell apoptosis

1H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal and F. Bray, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin. 71(3) (2021) 209–249; https://doi.org/10.3322/caac.21660Search in Google Scholar

2W. D. Travis, E. Brambilla and G. J. Riely, New pathologic classification of lung cancer: relevance for clinical practice and clinical trials, J. Clin. Oncol. 31(8) (2013) 992–1001; https://doi.org/10.1200/jco.2012.46.9270Search in Google Scholar

3A. T. Fathi and J. R. Brahmer, Chemotherapy for advanced stage non-small cell lung cancer, Semin. Thorac. Cardiovasc. Surg. 20(3) (2008) 210–216; https://doi.org/10.1053/j.semtcvs.2008.09.002Search in Google Scholar

4A. Díaz-Serrano, P. Gella, E. Jiménez, J. Zugazagoitia and L. Paz-Ares Rodríguez, Targeting EGFR in lung cancer: Current standards and developments, Drugs 78(9) (2018) 893–911; https://doi.org/10.1007/s40265-018-0916-4Search in Google Scholar

5M. Maemondo, A. Inoue, K. Kobayashi, S. Sugawara, S. Oizumi, H. Isobe, A. Gemma, M. Harada, H. Yoshizawa, I. Kinoshita, Y. Fujita, S. Okinaga, H. Hirano, K. Yoshimori, T. Harada, T. Ogura, M. Ando, H. Miyazawa, T. Tanaka, Y. Saijo, K. Hagiwara, S. Morita and T. Nukiwa, Gefitinib or chemo-therapy for non-small-cell lung cancer with mutated EGFR, N. Engl. J. Med. 362(25) (2010) 2380–2388; https://doi.org/10.1056/NEJMoa0909530Search in Google Scholar

6M. Reck, D. Rodríguez-Abreu, A. G. Robinson, R. Hui, T. Csőszi, A. Fülöp, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O’Brien, S. Rao, K. Hotta, M. A. Leiby, G. M. Lubiniecki, Y. Shentu, R. Rang-wala and J. R. Brahmer, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N. Engl. J. Med. 375(19) (2016) 1823–1833; https://doi.org/10.1056/NEJMoa1606774Search in Google Scholar

7J. Xie, J. Liu, H. Liu, S. Liang, M. Lin, Y. Gu, T. Liu, D. Wang, H. Ge and S. L. Mo, The antitumor effect of tanshinone IIA on anti-proliferation and decreasing VEGF/VEGFR2 expression on the human non-small cell lung cancer A549 cell line, Acta Pharm. Sin. B. 5(6) (2015) 554–563; https://doi.org/10.1016/j.apsb.2015.07.008Search in Google Scholar

8H. Luo, C. T. Vong, H. Chen, Y. Gao, P. Lyu, L. Qiu, M. Zhao, Q. Liu, Z. Cheng, J. Zou, P. Yao, C. Gao, J. Wei, C. O. L. Ung, S. Wang, Z. Zhong and Y. Wang, Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine, Chin. Med. 14 (2019) Article ID 48 (58 pages); https://doi.org/10.1186/s13020-019-0270-9Search in Google Scholar

9M. Kluska and K. Woźniak, Natural polyphenols as modulators of etoposide anti-cancer activity, Int. J. Mol. Sci. 22(12) (2021) Article ID 6602 (16 pages); https://doi.org/10.3390/ijms22126602Search in Google Scholar

10J. Liang, N. Bi, S. Wu, M. Chen, C. Lv, L. Zhao, A. Shi, W. Jiang, Y. Xu, Z. Zhou, W. Wang, D. Chen, Z. Hui, J. Lv, H. Zhang, Q. Feng, Z. Xiao, X. Wang, L. Liu, T. Zhang, L. Du, W. Chen, Y. Shyr, W. Yin, J. Li, J. He and L. Wang, Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial, Ann. Oncol. 28(4) (2017) 777–783; https://doi.org/10.1093/annonc/mdx009Search in Google Scholar

11Y. Yoneshima, S. Morita, M. Ando, A. Nakamura, S. Iwasawa, H. Yoshioka, Y. Goto, M. Takeshita, T. Harada, K. Hirano, T. Oguri, M. Kondo, S. Miura, Y. Hosomi, T. Kato, T. Kubo, J. Kishimoto, N. Yamamoto, Y. Nakanishi and I. Okamoto, Phase 3 trial comparing nanoparticle albumin-bound paclitaxel with docetaxel for previously treated advanced NSCLC, J. Thorac. Oncol. 16(9) (2021) 1523–1532; https://doi.org/10.1016/j.jtho.2021.03.027Search in Google Scholar

12X. Jiang, W. Zhao, F. Zhu, H. Wu, X. Ding, J. Bai, X. Zhang and M. Qian, Ligustilide inhibits the proliferation of non-small cell lung cancer via glycolytic metabolism, Toxicol. Appl. Pharmacol. 410 (2021) Article ID 115336 (25 pages); https://doi.org/10.1016/j.taap.2020.115336Search in Google Scholar

13J. Zou, Y. Yang, Y. Yang and X. Liu, Polydatin suppresses proliferation and metastasis of non-small cell lung cancer cells by inhibiting NLRP3 inflammasome activation via NF-κB pathway, Biomed. Pharmacother. 108 (2018) 130–136; https://doi.org/10.1016/j.biopha.2018.09.051Search in Google Scholar

14A. Ashaq, M. F. Maqbool, A. Maryam, M. Khan, H. A. Shakir, M. Irfan, J. I. Qazi, Y. Li and T. Ma, Hispidulin: A novel natural compound with therapeutic potential against human cancers, Phytother. Res. 35(2) (2021) 771–789; https://doi.org/10.1002/ptr.6862Search in Google Scholar

15K. S. Prabhu, A. A. Bhat, K. S. Siveen, S. Kuttikrishnan, S. S. Raza, T. Raheed, A. Jochebeth, A. Q. Khan, M. Z. Chawdhery, M. Haris, M. Kulinski, S. Dermime, M. Steinhoff and S. Uddin, Sanguinarine mediated apoptosis in non-small cell lung cancer via generation of reactive oxygen species and suppression of JAK/STAT pathway, Biomed. Pharmacother. 144 (2021) Article ID 112358 (11 pages); https://doi.org/10.1016/j.biopha.2021.112358Search in Google Scholar

16Y. Chen, L. Yin, M. Hao, W. Xu, J. Gao, Y. Sun, Q. Wang, S. Chen, Y. Liang, R. Guo, J. Zhang, J. Li, Q. Zhai, R. Cheng, J. Wang, H. Wang and Z. Yang, Medicarpin induces G1 arrest and mitochondria-mediated intrinsic apoptotic pathway in bladder cancer cells, Acta Pharm. 73(2) (2023) 211–225; https://doi.org/10.2478/acph-2023-0016Search in Google Scholar

17J. H. Kim, D. M. Kang, Y. J. Cho, J. W. Hyun and M. J. Ahn, Medicarpin increases antioxidant genes by inducing NRF2 transcriptional level in HeLa cells, Antioxidants (Basel) 11(2) (2022) Article ID 421 (10 pages); https://doi.org/10.3390/antiox11020421Search in Google Scholar

18B. Bhargavan, D. Singh, A. K. Gautam, J. S. Mishra, A. Kumar, A. Goel, M. Dixit, R. Pandey, L. Manic-kavasagam, S. D. Dwivedi, B. Chakravarti, G. K. Jain, R. Ramachandran, R. Maurya, A. Trivedi, N. Chattopadhyay and S. Sanyal, Medicarpin, a legume phytoalexin, stimulates osteoblast differentiation and promotes peak bone mass achievement in rats: evidence for estrogen receptor β-mediated osteogenic action of medicarpin, J. Nutr. Biochem. 23(1) (2012) 27–38; https://doi.org/10.1016/j.jnutbio.2010.11.002Search in Google Scholar

19A. M. Tyagi, A. K. Gautam, A. Kumar, K. Srivastava, B. Bhargavan, R. Trivedi, S. Saravanan, D. K. Yadav, N. Singh, C. Pollet, M. Brazier, R. Mentaverri, R. Maurya, N. Chattopadhyay, A. Goel and D. Singh, Medicarpin inhibits osteoclastogenesis and has nonestrogenic bone conserving effect in ovariectomized mice, Mol. Cell. Endocrinol. 325(1–2) (2010) 101–109; https://doi.org/10.1016/j.mce.2010.05.016Search in Google Scholar

20G. Gatouillat, A. A. Magid, E. Bertin, H. El btaouri, H. Morjani, C. Lavaud and C. Madoulet, Medicarpin and millepurpan, two flavonoids isolated from Medicago sativa, induce apoptosis and overcome multidrug resistance in leukemia P388 cells, Phytomedicine 22(13) (2015) 1186–1194; https://doi.org/10.1016/j.phymed.2015.09.005Search in Google Scholar

21R. Trivedi, R. Maurya and D. P. Mishra, Medicarpin, a legume phytoalexin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the induction of DR5 and activation of the ROSJNK-CHOP pathway, Cell Death Dis. 5(10) (2014) e1465; https://doi.org/10.1038/cddis.2014.429Search in Google Scholar

22A. K. Yiğin, H. Donmez, M. Hitit, S. Seven, N. Eser, E. Kurar and M. Seven, The effect of medicarpin on PTEN/AKT signal pathway in head and neck squamous cell carcinoma, J. Cancer Res. Ther. 18(1) (2022) 180–184; https://doi.org/10.4103/jcrt.jcrt_641_21Search in Google Scholar

23A. Mohr, L. Deedigan, S. Jencz, Y. Mehrabadi, L. Houlden, S. M. Albarenque and R. M. Zwacka, Caspase-10: a molecular switch from cell-autonomous apoptosis to communal cell death in response to chemotherapeutic drug treatment, Cell Death Differ. 25(2) (2018) 340–352; https://doi.org/10.1038/cdd.2017.164Search in Google Scholar

24H. S. Chin, M. X. Li, I. K. L. Tan, R. L. Ninnis, B. Reljic, K. Scicluna, L. F. Dagley, J. J. Sandow, G. L. Kelly, A. L. Samson, S. Chappaz, S. L. Khaw, C. Chang, A. Morokoff, K. Brinkmann, A. Webb, C. Hockings, C. M. Hall, A. J. Kueh, M. T. Ryan, R. M. Kluck, P. Bouillet, M. J. Herold, D. H. D. Gray, D. C. S. Huang, M. F. van Delft and G. Dewson, VDAC2 enables BAX to mediate apoptosis and limit tumor development, Nat. Commun. 9(1) (2018) Article ID 4976 (13 pages); https://doi.org/10.1038/s41467-018-07309-4Search in Google Scholar

25H. Xian and Y. C. Liou, Loss of MIEF1/MiD51 confers susceptibility to BAX-mediated cell death and PINK1-PRKN-dependent mitophagy, Autophagy 15(12) (2019) 2107–2125; https://doi.org/10.1080/15548627.2019.1596494Search in Google Scholar

26L. Bai, H. M. Ni, X. Chen, D. DiFrancesca and X. M. Yin, Deletion of Bid impedes cell proliferation and hepatic carcinogenesis, Am. J. Pathol. 166(5) (2005) 1523–1532; https://doi.org/10.1016/s0002-9440(10)62368-1Search in Google Scholar

27A. Wree, C. D. Johnson, J. Font-Burgada, A. Eguchi, D. Povero, M. Karin and A. E. Feldstein, Hepatocyte-specific Bid depletion reduces tumor development by suppressing inflammation-related compensatory proliferation, Cell Death Differ. 22(12) (2015) 1985–1994; https://doi.org/10.1038/cdd.2015.46Search in Google Scholar

28M. J. Morgan and Z. G. Liu, Crosstalk of reactive oxygen species and NF-κB signaling, Cell Res. 21(1) (2011) 103–115; https://doi.org/10.1038/cr.2010.178Search in Google Scholar

29C. Yu, S. Yan, B. Khambu, X. Chen, Z. Dong, J. Luo, G. K. Michalopoulos, S. Wu and X. M. Yin, Gene expression analysis indicates divergent mechanisms in DEN-induced carcinogenesis in wild type and Bid-deficient livers, PLoS One 11(5) (2016) e0155211; https://doi.org/10.1371/journal.pone.0155211Search in Google Scholar

30S. H. Moon, C. H. Huang, S. L. Houlihan, K. Regunath, W. A. Freed-Pastor, J. P. t. Morris, D. F. Tschaharganeh, E. R. Kastenhuber, A. M. Barsotti, R. Culp-Hill, W. Xue, Y. J. Ho, T. Baslan, X. Li, A. Mayle, E. de Stanchina, L. Zender, D. R. Tong, A. D’Alessandro, S. W. Lowe and C. Prives, p53 represses the mevalonate pathway to mediate tumor suppression, Cell 176(3) (2019) 564–580; https://doi.org/10.1016/j.cell.2018.11.011Search in Google Scholar

31D. Reddy, R. Kumavath, P. Ghosh and D. Barh, Lanatoside C induces G2/M cell cycle arrest and suppresses cancer cell growth by attenuating MAPK, Wnt, JAK-STAT, and PI3K/AKT/mTOR signaling pathways, Biomolecules 9(12) (2019) Article ID 792 (20 pages); https://doi.org/10.3390/biom9120792Search in Google Scholar

32W. Hao, S. Wang and Z. Zhou, Tubeimoside-1 (TBMS1) inhibits lung cancer cell growth and induces cells apoptosis through activation of MAPK-JNK pathway, Int. J. Clin. Exp. Pathol. 8(10) (2015) 12075–12083.Search in Google Scholar

33X. B. Jia, Q. Zhang, L. Xu, W. J. Yao and L. Wei, Lotus leaf flavonoids induce apoptosis of human lung cancer A549 cells through the ROS/p38 MAPK pathway, Biol. Res. 54(1) (2021) Article ID 7 (15 pages); https://doi.org/10.1186/s40659-021-00330-wSearch in Google Scholar

34T. Otto and P. Sicinski, Cell cycle proteins as promising targets in cancer therapy, Nat. Rev. Cancer 17(2) (2017) 93–115; https://doi.org/10.1038/nrc.2016.138Search in Google Scholar

35Y. Hu, K. Yu, G. Wang, D. Zhang, C. Shi, Y. Ding, D. Hong, D. Zhang, H. He, L. Sun, J. N. Zheng, S. Sun and F. Qian, Lanatoside C inhibits cell proliferation and induces apoptosis through attenuating Wnt/β-catenin/c-Myc signaling pathway in human gastric cancer cell, Biochem. Pharmacol. 150 (2018) 280–292; https://doi.org/10.1016/j.bcp.2018.02.023Search in Google Scholar

36M. Rasheduzzaman, H. Yin and S. Y. Park, Cardiac glycoside sensitized hepatocellular carcinoma cells to TRAIL via ROS generation, p38MAPK, mitochondrial transition, and autophagy mediation, Mol. Carcinog. 58(11) (2019) 2040–2051; https://doi.org/10.1002/mc.23096Search in Google Scholar

37I. Durmaz, E. B. Guven, T. Ersahin, M. Ozturk, I. Calis and R. Cetin-Atalay, Liver cancer cells are sensitive to lanatoside C induced cell death independent of their PTEN status, Phytomedicine 23(1) (2016) 42–51; https://doi.org/10.1016/j.phymed.2015.11.012Search in Google Scholar

38A. Rauf, T. Abu-Izneid, A. A. Khalil, M. Imran, Z. A. Shah, T. B. Emran, S. Mitra, Z. Khan, F. A. Alhu maydhi, A. S. M. Aljohani, I. Khan, M. M. Rahman, P. Jeandet and T. A. Gondal, Berberine as a potential anticancer agent: A comprehensive review, Molecules 26(23) (2021) Article ID 7368 (19 pages); https://doi.org/10.3390/molecules26237368+Search in Google Scholar

39D. Bertheloot, E. Latz and B. S. Franklin, Necroptosis, pyroptosis and apoptosis: an intricate game of cell death, Cell. Mol. Immunol. 18(5) (2021) 1106–1121; https://doi.org/10.1038/s41423-020-00630-3Search in Google Scholar

40D. E. Hong, J. E. Yu, J. W. Lee, D. J. Son, H. P. Lee, Y. Kim, J. Y. Chang, D. W. Lee, W. K. Lee, J. Yun, S. B. Han, B. Y. Hwang and J. T. Hong, A natural CHI3L1-targeting compound, ebractenoid f, inhibits lung cancer cell growth and migration and induces apoptosis by blocking CHI3L1/AKT signals, Molecules 28(1) (2022) Article ID 329 (16 pages); https://doi.org/10.3390/molecules28010329Search in Google Scholar